Balance Sheet
Accounts PayablesAccumulated ExpensesCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent TaxesGoodwill & IntangiblesInventoryLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zhengye Biotechnology Holding (ZYBT) Current Deferred Revenue: 2023-2024

Historic Current Deferred Revenue for Zhengye Biotechnology Holding (ZYBT) over the last 2 years, with Dec 2024 value amounting to $477,000.

  • Zhengye Biotechnology Holding's Current Deferred Revenue fell 25.35% to $477,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $477,000, marking a year-over-year decrease of 25.35%. This contributed to the annual value of $477,000 for FY2024, which is 26.73% down from last year.
  • Zhengye Biotechnology Holding's Current Deferred Revenue amounted to $477,000 in FY2024, which was down 26.73% from $651,052 recorded in FY2023.
  • Over the past 5 years, Zhengye Biotechnology Holding's Current Deferred Revenue peaked at $651,052 during FY2023, and registered a low of $477,000 during FY2024.
  • For the 2-year period, Zhengye Biotechnology Holding's Current Deferred Revenue averaged around $564,026, with its median value being $564,026 (2023).
  • Data for Zhengye Biotechnology Holding's Current Deferred Revenue shows a maximum YoY fell of 26.73% (in 2024) over the last 5 years.
  • Over the past 2 years, Zhengye Biotechnology Holding's Current Deferred Revenue (Yearly) stood at $651,052 in 2023, then declined by 26.73% to $477,000 in 2024.